Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment develops, manufactures, and sells tools, such as Biologics platform that enables researchers interrogate protein purity and identify contaminants during the development and production of biologics; Simple Western platform for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment offers controls and calibrators for hematology clinical instruments; blood chemistry and blood gas quality controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market; bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry; and Paratest, a novel and convenient stool collection and test device for the veterinary market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:TECH
CUSIP87837710
Phone612-379-8854
Debt
Debt-to-Equity Ratio0.37
Current Ratio5.55
Quick Ratio4.30
Price-To-Earnings
Trailing P/E Ratio44.67
Forward P/E Ratio37.93
P/E Growth2.24
Sales & Book Value
Annual Sales$563 million
Price / Sales10.25
Cash Flow$5.0834 per share
Price / Cash30.22
Book Value$25.44 per share
Price / Book6.04
Profitability
EPS (Most Recent Fiscal Year)$3.42
Net Income$76.08 million
Net Margins18.29%
Return on Equity14.75%
Return on Assets9.35%
Miscellaneous
Employees1,800
Outstanding Shares37,570,000
Market Cap$5,728.89
BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions
What is BIO-TECHNE's stock symbol?
BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."
How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?
BIO-TECHNE announced a quarterly dividend on Thursday, May 3rd. Stockholders of record on Monday, May 14th will be paid a dividend of $0.32 per share on Friday, May 25th. This represents a $1.28 annualized dividend and a dividend yield of 0.83%. The ex-dividend date is Friday, May 11th. View BIO-TECHNE's Dividend History.
How were BIO-TECHNE's earnings last quarter?
BIO-TECHNE Corp (NASDAQ:TECH) announced its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported $1.21 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.14 by $0.07. The biotechnology company earned $164 million during the quarter, compared to analysts' expectations of $163.43 million. BIO-TECHNE had a net margin of 18.29% and a return on equity of 14.75%. The company's revenue was up 13.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.97 earnings per share. View BIO-TECHNE's Earnings History.
When is BIO-TECHNE's next earnings date?
What price target have analysts set for TECH?
6 equities research analysts have issued 1 year target prices for BIO-TECHNE's shares. Their predictions range from $115.00 to $185.00. On average, they anticipate BIO-TECHNE's share price to reach $157.00 in the next year. This suggests a possible upside of 2.3% from the stock's current price. View Analyst Ratings for BIO-TECHNE.
What is the consensus analysts' recommendation for BIO-TECHNE?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of BIO-TECHNE's key competitors?
Some companies that are related to BIO-TECHNE include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), argenx (ARGX), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Halozyme Therapeutics (HALO) and Momenta Pharmaceuticals (MNTA).
Who are BIO-TECHNE's key executives?
BIO-TECHNE's management team includes the folowing people:
- Mr. Charles R. Kummeth, Pres, CEO & Director (Age 58)
- Mr. James T. Hippel, Sr. VP of Fin., CFO & Principal Accounting Officer (Age 47)
- Mr. N. David Eansor, Sr. VP of Biotechnology Division (Age 57)
- Mr. Robert M. Gavin, Sr. VP of Protein Platforms Division (Age 50)
- Mr. Kevin S. Gould, Sr. VP of Diagnostics Division (Age 52)
Has BIO-TECHNE been receiving favorable news coverage?
Media stories about TECH stock have been trending somewhat negative on Thursday, according to Accern. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BIO-TECHNE earned a coverage optimism score of -0.02 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 44.75 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are BIO-TECHNE's major shareholders?
BIO-TECHNE's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (1.37%), Fred Alger Management Inc. (1.33%), Summit Creek Advisors LLC (0.29%), Confluence Investment Management LLC (0.08%), First National Bank of Omaha (0.07%) and Bank of Montreal Can (0.05%). Company insiders that own BIO-TECHNE stock include Charles A Dinarello, Charles R Kummeth, John L Higgins, Karen A Holbrook, Kevin S Gould, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for BIO-TECHNE.
Which major investors are selling BIO-TECHNE stock?
TECH stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Summit Creek Advisors LLC, First National Bank of Omaha, Bremer Trust National Association, State of Alaska Department of Revenue and Confluence Investment Management LLC. Company insiders that have sold BIO-TECHNE company stock in the last year include Charles A Dinarello, Charles R Kummeth, Karen A Holbrook, Robert V Baumgartner and Roger C Lucas. View Insider Buying and Selling for BIO-TECHNE.
Which major investors are buying BIO-TECHNE stock?
TECH stock was bought by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Bank of Montreal Can, Nisa Investment Advisors LLC, Affiance Financial LLC, Pendal Group Ltd, Wendell David Associates Inc., Contravisory Investment Management Inc. and Amalgamated Bank. View Insider Buying and Selling for BIO-TECHNE.
How do I buy shares of BIO-TECHNE?
Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BIO-TECHNE's stock price today?
One share of TECH stock can currently be purchased for approximately $153.47.
How big of a company is BIO-TECHNE?
BIO-TECHNE has a market capitalization of $5.73 billion and generates $563 million in revenue each year. The biotechnology company earns $76.08 million in net income (profit) each year or $3.42 on an earnings per share basis. BIO-TECHNE employs 1,800 workers across the globe.
How can I contact BIO-TECHNE?
BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]
MarketBeat Community Rating for BIO-TECHNE (NASDAQ TECH)
MarketBeat's community ratings are surveys of what our community members think about BIO-TECHNE and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.
